Great report takeaway: Valuation range of A$0.016-A$0.021 per share
We continue to value Invion at A$0.016-A$0.021 per share
using a weighted DCF approach. Although Invion’s valuation
has retreated from the highs of 2021, along with the broader
biotechnology sector, we believe that Invion has the potential
to re-rate as the clinical development of INV043 de-risks its
future prospects. Please see page 11 for key risks.
ASX:IVX - Latest research update on Invion from Pitt Street, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $25.69M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $7.245K | 1.811M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 27102012 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7857961 | 27 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |